Overview

Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel. The structure for the study is a single arm, non-randomized, open- label, multicenter trial with no control group.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel